Latest Ratios: P/E Ratio -0.3x · EV/EBITDA N/A · ROE N/A. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $138M | $129M | $76M | $151M | $263M | $432M | — | — | — |
| Enterprise Value | $-255722489 | $-264361993 | $26M | $155M | $244M | $330M | — | — | — |
| P/E Ratio → | -0.29 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 0.79 | 1.00 | 1.05 | 2.00 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -94.5% | -58.7% | -39.5% | -52.1% | -155.0% | -2483.2% | — |
| ROA | -229.3% | -229.3% | -66.3% | -46.3% | -34.0% | -43.3% | -101.1% | -200.1% | -412.3% |
| ROIC | — | — | -90.2% | -48.9% | -40.5% | -78.1% | -338.8% | — | — |
| ROCE | -132.0% | -132.0% | -76.1% | -52.5% | -36.0% | -46.3% | -118.3% | -2386.5% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.33 | 0.24 | 0.16 | 0.08 | 0.38 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -0.52 | 0.03 | -0.07 | -0.47 | -0.63 | -0.85 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | -16.83 | -3.14 |
Net cash position: cash ($396M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.20 | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 | 4.81 | 3.45 | 0.12 |
| Quick Ratio | 18.20 | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 | 4.81 | 3.45 | 0.12 |
| Cash Ratio | 18.08 | 18.08 | 4.94 | 8.81 | 17.55 | 20.43 | 4.76 | 2.96 | 0.12 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $10M | $3M | $3M | $2M | $2M | $2M | $2M | $283024 |
Clinical Trial Execution Risk
As reported in financial statements, Vor's ROIC has consistently trended in negative territory, reaching -53.5% in 2025Q1, which underscores the company's current inability to generate productive returns on invested capital while it remains in a purely research-intensive, pre-revenue phase of its corporate lifecycle.
The persistent decay in ROIC reflects the heavy burden of clinical trial expenditures that are not yet offset by any commercial product revenue. Investors should monitor this metric as a proxy for the company's success in optimizing its R&D spend, as any improvement would suggest better capital allocation efficiency.
Based on recent SEC filings, the company's current ratio has experienced extreme volatility, dropping from a peak of 31.15 in 2026Q1 to lower levels, indicating that the firm's liquidity position is highly sensitive to the timing of capital raises and the ongoing burn of its cash reserves.
While the current ratio appears high in certain periods, it is largely a function of cash-on-hand rather than operational working capital efficiency. The rapid fluctuation in liquidity suggests that the company's ability to sustain operations is entirely dependent on its ability to manage its cash runway effectively.
According to reported figures, the company's DPO has shown significant variability, reaching 9,916 days in 2026Q1, which suggests that the firm's accounts payable management is not yet reflective of a stable, recurring operational model but rather reflects lumpy, project-based clinical trial vendor payments.
The lack of meaningful asset turnover or consistent CCC metrics is expected for a pre-revenue biotech entity. This volatility implies that investors should focus on cash burn rates rather than traditional working capital efficiency ratios, which are currently distorted by the absence of commercial revenue.
As indicated by the company's financial data, the Price-to-Book ratio is a fundamentally flawed metric for Vor, as the firm's negative equity position of -$150.4 million in 2026Q1 renders traditional book value analysis entirely meaningless for assessing the company's true intrinsic value or future potential.
Investors often rely on P/B to gauge value in industrial firms, but for a clinical-stage biotech, this ratio obscures the value of the intellectual property and the potential of the VOR33 platform. A more appropriate focus would be the enterprise value relative to the projected clinical milestones and the remaining cash runway.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VOR stock.
Vor Biopharma Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
Based on historical data, Vor Biopharma Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.